Market Overview:
The global proto-oncogene drgu market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The market growth can be attributed to factors such as rising incidences of cancer, increasing geriatric population, and technological advancements in the field of oncology. However, the high cost associated with proto-oncogene drugs is expected to restrain the growth of this market during the forecast period. Based on type, the global proto-oncogene drgu market can be segmented into axitinib (Inlyta), ponatinib (Iclusig), imatinib (Gleevec), sunitinib (Sutent), pazopanib (Votrient), dabrafenib (Tafinlar), vandetanib (Caprelsa), vemurafenib(Zelboraf) and cabozantinip(Cabometyx and Cometriq). Based on application, this market can be segmented into clinic, hospital and others segments. Geographically, this market can be segmented into North America, Latin America Europe Asia Pacific Middle East & Africa).
Product Definition:
A proto-oncogene is a gene that can become an oncogene, or cancer-causing gene. Proto-oncogenes are normal genes that help cells grow and divide. But if they become mutated, they can contribute to the development of cancer.
Axitinib (Inlyta):
Axitinib (Inlyta), a JAK1 & 2 inhibitor, is indicated for the treatment of patients with advanced/metastatic renal cell carcinoma and non-small cell lung cancer. It is an oral drug with a fixed dose combination of sunitinib malate and vandiparoxine. The product was approved by the FDA in March 2013 for sale in the U.S.
Ponatinib (Iclusig):
Ponatinib (Iclusig) is a drug that is under investigation for the treatment of patients with advanced glioblastoma multiforme. The U.S. FDA has approved it as a second-line therapy, after chemotherapy and before radiation therapy in patients with recurrent or metastatic glioblastoma who are 18 years or older and have been treated previously with at least one line of chemotherapy.
Application Insights:
The others segment held the largest share of the global proto-oncogene drgu market in 2017. This is due to rising incidence of cancer across the globe and increasing government funding for cancer research. For instance, as per data published by WHO, an estimated 9.6 million new cases were reported globally in 2016 which resulted in death of around 6.5 million people that year alone. In addition, according to a study published by NCBI, it is estimated that around 5-10% patients suffering from chronic kidney disease (CKD) develop nephrological cancers over a period of 5 years which accounts for nearly 1/3rd - 2/3rds patients suffering from CKD worldwide respectively thus driving demand for effective treatment options such as ponatinib mesylate (Iclusig).
However, revenue generated through prescription drugs sold via traditional channels such as pharmacies.
Regional Analysis:
North America dominated the global market in 2017. Key factors driving the growth include presence of key players, high R&D expenditure by companies, and availability of branded drugs for treatment of various cancers. Moreover, increasing number of clinical trials and approval process expeditiously completed are also contributing to the growth. For instance, in December 2016 Sun Pharma & Indian Ltd., announced that Iclusig received accelerated approval from U.S FDA (Food and Drug Administration) for treatment-related purposes only.
Asia Pacific is expected to witness lucrative CAGR over the forecast period owing to increase in healthcare spending by governments along with other initiatives taken up by non-profit organizations such as WHO & APCOS (Asian Pacific Cancer Care Organization).
Growth Factors:
- Increasing prevalence of cancer
- Rising demand for personalized medicines
- Technological advancements in cancer diagnosis and treatment
- Growing awareness about cancer prevention and early detection
- increasing investment in research and development of novel oncology drugs
Scope Of The Report
Report Attributes
Report Details
Report Title
Proto-Oncogene Drgu Market Research Report
By Type
Axitinib (Inlyta), Ponatinib (Iclusig), Imatinib (Gleevec), Sunitinib (Sutent), Pazopanib (Votrient), Dabrafenib (Tafinlar), Vandetanib (Caprelsa), Vemurafenib (Zelboraf), Cabozantinib (Cabometyx and Cometriq), Sorafenib (Nexavar)
By Application
Clinic, Hospital, Others
By Companies
ARIAD Pharmaceuticals, AstraZeneca, Bayer Healthcare, Bristol-Myers Squibb, ChemGenex Pharmaceuticals, Dexa Medica, Eisai Pharmaceuticals, Exelixis, GlaxoSmithKline, Novartis, Onyx Pharmaceuticals, Plexxikon, Pfizer
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
230
Number of Tables & Figures
161
Customization Available
Yes, the report can be customized as per your need.
Global Proto-Oncogene Drgu Market Report Segments:
The global Proto-Oncogene Drgu market is segmented on the basis of:
Types
Axitinib (Inlyta), Ponatinib (Iclusig), Imatinib (Gleevec), Sunitinib (Sutent), Pazopanib (Votrient), Dabrafenib (Tafinlar), Vandetanib (Caprelsa), Vemurafenib (Zelboraf), Cabozantinib (Cabometyx and Cometriq), Sorafenib (Nexavar)
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinic, Hospital, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- ARIAD Pharmaceuticals
- AstraZeneca
- Bayer Healthcare
- Bristol-Myers Squibb
- ChemGenex Pharmaceuticals
- Dexa Medica
- Eisai Pharmaceuticals
- Exelixis
- GlaxoSmithKline
- Novartis
- Onyx Pharmaceuticals
- Plexxikon
- Pfizer
Highlights of The Proto-Oncogene Drgu Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Axitinib (Inlyta)
- Ponatinib (Iclusig)
- Imatinib (Gleevec)
- Sunitinib (Sutent)
- Pazopanib (Votrient)
- Dabrafenib (Tafinlar)
- Vandetanib (Caprelsa)
- Vemurafenib (Zelboraf)
- Cabozantinib (Cabometyx and Cometriq)
- Sorafenib (Nexavar)
- By Application:
- Clinic
- Hospital
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Proto-Oncogene Drgu Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
The Proto-Oncogene Drgu is a gene that may play a role in the development of cancer.
Some of the major companies in the proto-oncogene drgu market are ARIAD Pharmaceuticals, AstraZeneca, Bayer Healthcare, Bristol-Myers Squibb, ChemGenex Pharmaceuticals, Dexa Medica, Eisai Pharmaceuticals, Exelixis, GlaxoSmithKline, Novartis, Onyx Pharmaceuticals, Plexxikon, Pfizer.
The proto-oncogene drgu market is expected to register a CAGR of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Proto-Oncogene Drgu Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Proto-Oncogene Drgu Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Proto-Oncogene Drgu Market - Supply Chain
4.5. Global Proto-Oncogene Drgu Market Forecast
4.5.1. Proto-Oncogene Drgu Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Proto-Oncogene Drgu Market Size (000 Units) and Y-o-Y Growth
4.5.3. Proto-Oncogene Drgu Market Absolute $ Opportunity
5. Global Proto-Oncogene Drgu Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Proto-Oncogene Drgu Market Size and Volume Forecast by Type
5.3.1. Axitinib (Inlyta)
5.3.2. Ponatinib (Iclusig)
5.3.3. Imatinib (Gleevec)
5.3.4. Sunitinib (Sutent)
5.3.5. Pazopanib (Votrient)
5.3.6. Dabrafenib (Tafinlar)
5.3.7. Vandetanib (Caprelsa)
5.3.8. Vemurafenib (Zelboraf)
5.3.9. Cabozantinib (Cabometyx and Cometriq)
5.3.10. Sorafenib (Nexavar)
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Proto-Oncogene Drgu Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Proto-Oncogene Drgu Market Size and Volume Forecast by Application
6.3.1. Clinic
6.3.2. Hospital
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Proto-Oncogene Drgu Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Proto-Oncogene Drgu Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Proto-Oncogene Drgu Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Proto-Oncogene Drgu Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Proto-Oncogene Drgu Demand Share Forecast, 2019-2026
9. North America Proto-Oncogene Drgu Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Proto-Oncogene Drgu Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Proto-Oncogene Drgu Market Size and Volume Forecast by Application
9.4.1. Clinic
9.4.2. Hospital
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Proto-Oncogene Drgu Market Size and Volume Forecast by Type
9.7.1. Axitinib (Inlyta)
9.7.2. Ponatinib (Iclusig)
9.7.3. Imatinib (Gleevec)
9.7.4. Sunitinib (Sutent)
9.7.5. Pazopanib (Votrient)
9.7.6. Dabrafenib (Tafinlar)
9.7.7. Vandetanib (Caprelsa)
9.7.8. Vemurafenib (Zelboraf)
9.7.9. Cabozantinib (Cabometyx and Cometriq)
9.7.10. Sorafenib (Nexavar)
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Proto-Oncogene Drgu Demand Share Forecast, 2019-2026
10. Latin America Proto-Oncogene Drgu Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Proto-Oncogene Drgu Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Proto-Oncogene Drgu Market Size and Volume Forecast by Application
10.4.1. Clinic
10.4.2. Hospital
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Proto-Oncogene Drgu Market Size and Volume Forecast by Type
10.7.1. Axitinib (Inlyta)
10.7.2. Ponatinib (Iclusig)
10.7.3. Imatinib (Gleevec)
10.7.4. Sunitinib (Sutent)
10.7.5. Pazopanib (Votrient)
10.7.6. Dabrafenib (Tafinlar)
10.7.7. Vandetanib (Caprelsa)
10.7.8. Vemurafenib (Zelboraf)
10.7.9. Cabozantinib (Cabometyx and Cometriq)
10.7.10. Sorafenib (Nexavar)
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Proto-Oncogene Drgu Demand Share Forecast, 2019-2026
11. Europe Proto-Oncogene Drgu Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Proto-Oncogene Drgu Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Proto-Oncogene Drgu Market Size and Volume Forecast by Application
11.4.1. Clinic
11.4.2. Hospital
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Proto-Oncogene Drgu Market Size and Volume Forecast by Type
11.7.1. Axitinib (Inlyta)
11.7.2. Ponatinib (Iclusig)
11.7.3. Imatinib (Gleevec)
11.7.4. Sunitinib (Sutent)
11.7.5. Pazopanib (Votrient)
11.7.6. Dabrafenib (Tafinlar)
11..7. Vandetanib (Caprelsa)
11.7.8. Vemurafenib (Zelboraf)
11.7.9. Cabozantinib (Cabometyx and Cometriq)
11.7.10. Sorafenib (Nexavar)
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Proto-Oncogene Drgu Demand Share, 2019-2026
12. Asia Pacific Proto-Oncogene Drgu Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Proto-Oncogene Drgu Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Proto-Oncogene Drgu Market Size and Volume Forecast by Application
12.4.1. Clinic
12.4.2. Hospital
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Proto-Oncogene Drgu Market Size and Volume Forecast by Type
12.7.1. Axitinib (Inlyta)
12.7.2. Ponatinib (Iclusig)
12.7.3. Imatinib (Gleevec)
12.7.4. Sunitinib (Sutent)
12.7.5. Pazopanib (Votrient)
12.7.6. Dabrafenib (Tafinlar)
12.7.7. Vandetanib (Caprelsa)
12.7.8. Vemurafenib (Zelboraf)
12.7.9. Cabozantinib (Cabometyx and Cometriq)
12.7.10. Sorafenib (Nexavar)
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Proto-Oncogene Drgu Demand Share, 2019-2026
13. Middle East & Africa Proto-Oncogene Drgu Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Proto-Oncogene Drgu Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Proto-Oncogene Drgu Market Size and Volume Forecast by Application
13.4.1. Clinic
13.4.2. Hospital
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Proto-Oncogene Drgu Market Size and Volume Forecast by Type
13.7.1. Axitinib (Inlyta)
13.7.2. Ponatinib (Iclusig)
13.7.3. Imatinib (Gleevec)
13.7.4. Sunitinib (Sutent)
13.7.5. Pazopanib (Votrient)
13.7.6. Dabrafenib (Tafinlar)
13.7.7. Vandetanib (Caprelsa)
13.7.8. Vemurafenib (Zelboraf)
13.7.9. Cabozantinib (Cabometyx and Cometriq)
13.7.10. Sorafenib (Nexavar)
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Proto-Oncogene Drgu Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Proto-Oncogene Drgu Market: Market Share Analysis
14.2. Proto-Oncogene Drgu Distributors and Customers
14.3. Proto-Oncogene Drgu Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. ARIAD Pharmaceuticals
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. AstraZeneca
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Bayer Healthcare
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Bristol-Myers Squibb
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. ChemGenex Pharmaceuticals
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Dexa Medica
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Eisai Pharmaceuticals
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Exelixis
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. GlaxoSmithKline
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Novartis
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Onyx Pharmaceuticals
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Plexxikon
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Pfizer
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
&n
